Agenus (NASDAQ:AGEN) Receives Buy Rating from HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $40.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 223.89% from the company’s previous close.

AGEN has been the subject of a number of other reports. B. Riley decreased their price target on Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 18th. StockNews.com started coverage on Agenus in a research report on Wednesday, April 17th. They set a “hold” rating on the stock.

Agenus Stock Up 3.7 %

AGEN opened at $12.35 on Friday. Agenus has a 52 week low of $4.78 and a 52 week high of $42.60. The business has a fifty day simple moving average of $10.21 and a 200-day simple moving average of $12.86. The firm has a market cap of $259.35 million, a P/E ratio of -0.96 and a beta of 1.25.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The company had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $54.21 million. Sell-side analysts expect that Agenus will post -9.7 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Institutional investors have recently added to or reduced their stakes in the business. PCG Wealth Advisors LLC boosted its holdings in Agenus by 65.7% in the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 18,850 shares in the last quarter. RPO LLC acquired a new stake in shares of Agenus during the 4th quarter worth $43,000. First Command Advisory Services Inc. acquired a new stake in shares of Agenus during the 3rd quarter worth $80,000. Ables Iannone Moore & Associates Inc. acquired a new stake in shares of Agenus during the 4th quarter worth $65,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Agenus by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock worth $89,000 after buying an additional 27,137 shares during the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.